FISHER RICHARD W sold (to issuer) $86K of THC

FISHER RICHARD W sold (to issuer) 493 shares of TENET HEALTHCARE CORP (THC) at $173.78 on 2026-05-22.

Original reporting
SEC EDGAR · FISHER RICHARD W
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

The disclosure provides ownership-change information but does not include any company-specific catalyst; trading impact is likely limited unless it signals a broader insider behavior shift.

02

Market read

A director’s sale to the issuer is typically low-signal for fundamentals, suggesting limited trading edge absent corroborating news or insider-trend context.

03

What to watch

Check for clustering of insider sales across multiple filings and whether other directors/officers are also trimming around the same dates; that pattern would matter more than this single Form 4.

Relevance 6/10Timing: Immediate (same-day/next-session digestion of Form 4), but typically not a driver of follow-through.

Background

The filing is an SEC Form 4 insider transaction disclosure for Tenet Healthcare director Richard W. Fisher.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Richard W. Fisher sold 493 shares to the issuer on 2026-05-22 at $173.78/share, per SEC Form 4.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-noise unless part of a broader insider trend.

Evidence & confidence

Form 4 details a small director sale to issuer under code D, with no 10b5-1 plan and no accompanying company news (earnings, guidance, deals, litigation).

Market effects

Minimal; single insider Form 4 without company fundamentals rarely resets sector expectations.

None indicated.

None indicated.

Counterpoint

Because the transaction is a sale to the issuer (often buyback/plan mechanics), it may not reflect bearish views on Tenet’s prospects.

Key entities

  • TENET HEALTHCARE CORP

    Subject of the Form 4 insider transaction; director sold shares to the issuer.

  • FISHER RICHARD W

    Tenet Healthcare director who reported the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HCAMed

Hospital Stocks Soared as Democrats Took Congress

HCA Healthcare (HCA) rose 10.34% to $510.70 on November 4, 2026, following Democratic gains in the U.S. election. Investors anticipate potential policy changes favoring hospitals and Medicaid insurers. Universal Health Services (UHS) and Tenet Healthcare (THC) also saw significant gains. HCA's stock is now valued at $106.68 billion, but analysts warn of potential downside risks if policy changes do not materialize.

$THCHighAI 8/10

Mizuho raises Tenet Healthcare stock price target on strong results

Mizuho increased its price target for Tenet Healthcare (NYSE:THC) to $305 from $290, citing strong quarterly results and raised 2026 EBITDA estimates. The stock trades near its 52-week high after a 49% six-month surge. Tenet reported Q3 2026 EPS of $6.64, beating estimates, and raised its full-year EBITDA outlook. Guggenheim maintained a Buy rating with a slightly lowered target of $306.

$THCMed

Tenet Healthcare Q3 Earnings Call Highlights

Tenet Healthcare (THC) reported Q3 earnings, with hospital segment showing 3.2% growth in admissions and 11% adjusted EBITDA increase. Revenue per admission rose 0.2% YoY. Exchange admissions and revenues declined 18%. Conifer transition activities contributed $147M, with $450M expected in 2026. Tenet generated $1.1B in adjusted free cash flow and repurchased 970K shares.